Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

439 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Potential drug-drug interactions and risk of unplanned hospitalization in older patients with cancer: A survey of the prospective ELCAPA (ELderly CAncer PAtients) cohort.
Beinse G, Reitter D, Segaux L, Carvahlo-Verlinde M, Rousseau B, Tournigand C, Cudennec T, Laurent M, Boudou-Rouquette P, Paillaud E, Canouï-Poitrine F, Caillet P; ELCAPA Study Group. Beinse G, et al. Among authors: rousseau b. J Geriatr Oncol. 2020 May;11(4):586-592. doi: 10.1016/j.jgo.2019.07.023. Epub 2019 Aug 21. J Geriatr Oncol. 2020. PMID: 31445850
Impact of the IDEA Collaboration Study Results on Clinical Practice in France for Patients With Stage III Colon Cancer: A National GERCOR - PRODIGE Survey.
Ouali K, Turpin A, Neuzillet C, Rousseau B, Garcia-Larnicol ML, Tournigand C, Samalin E, Taieb J, André T, Cohen R. Ouali K, et al. Among authors: rousseau b. Clin Colorectal Cancer. 2021 Mar;20(1):79-83.e4. doi: 10.1016/j.clcc.2020.11.004. Epub 2020 Nov 14. Clin Colorectal Cancer. 2021. PMID: 33281064 Free article.
Impact of trough concentrations of regorafenib and its major metabolites M-2 and M-5 on overall survival of chemorefractory metastatic colorectal cancer patients: Results from a multicentre GERCOR TEXCAN phase II study.
Rousseau B, Boukerma AK, Henriques J, Cohen R, Lucidarme O, Borg C, Tournigand C, Kim S, Bachet JB, Mazard T, Louvet C, Chibaudel B, Vernerey D, Andre T, Hulin A. Rousseau B, et al. Eur J Cancer. 2022 Jun;168:99-107. doi: 10.1016/j.ejca.2022.03.009. Epub 2022 Apr 27. Eur J Cancer. 2022. PMID: 35489233 Free PMC article. Clinical Trial.
Unravelling the pharmacologic opportunities and future directions for targeted therapies in gastro-intestinal cancers part 2: Neuroendocrine tumours, hepatocellular carcinoma, and gastro-intestinal stromal tumours.
Neuzillet C, de Mestier L, Rousseau B, Mir O, Hebbar M, Kocher HM, Ruszniewski P, Tournigand C. Neuzillet C, et al. Among authors: rousseau b. Pharmacol Ther. 2018 Jan;181:49-75. doi: 10.1016/j.pharmthera.2017.07.006. Epub 2017 Jul 16. Pharmacol Ther. 2018. PMID: 28723416 Review.
PD-L1 expression in perihilar and intrahepatic cholangiocarcinoma.
Fontugne J, Augustin J, Pujals A, Compagnon P, Rousseau B, Luciani A, Tournigand C, Cherqui D, Azoulay D, Pawlotsky JM, Calderaro J. Fontugne J, et al. Among authors: rousseau b. Oncotarget. 2017 Apr 11;8(15):24644-24651. doi: 10.18632/oncotarget.15602. Oncotarget. 2017. PMID: 28445951 Free PMC article.
439 results